WuXi Biologics and Sinorda Biomedicine Join Forces for Bispecific Antibody Development

Strategic Partnership between WuXi Biologics and Sinorda Biomedicine

In a significant development in the biotechnology field, WuXi Biologics (2269.HK) has entered into a strategic collaboration with Sinorda Biomedicine to enhance the research and manufacturing of SND006, an innovative bispecific antibody aimed at treating inflammatory bowel disease (IBD) and various autoimmune disorders. The announcement was made on January 28, 2026, marking a pivotal moment for both organizations as they aim to expedite the clinical development of this promising therapeutic agent.

Under the terms of this collaboration, Sinorda Biomedicine will benefit from WuXi Biologics' vast experience in biopharmaceutical development and manufacturing capabilities. This partnership will focus on advancing SND006 through preclinical pharmacological studies and clinical supply, effectively streamlining the Investigational New Drug (IND) application process. Notably, Sinorda Biomedicine, which holds the global rights for SND006, has already conducted successful in vitro validation studies and intends to submit IND applications to both the National Medical Products Administration (NMPA) in China and the U.S. Food and Drug Administration (FDA) in 2026.

Dr. Chris Chen, CEO of WuXi Biologics, expressed enthusiasm about the collaboration, highlighting the firm’s extensive track record with bispecific and multispecific antibodies. He stated, “Over the past decade, we have accumulated experience across hundreds of projects in bispecific and multispecific antibodies, which have become one of our fastest-growing areas.” Chen is optimistic about leveraging WuXi's integrated technology platforms to facilitate the swift development of SND006.

On the other hand, Dr. Pingsheng Hu, Chairman and General Manager of Sinorda Biomedicine, emphasized the potential of SND006, calling it a potentially best-in-class bispecific antibody that could lead to breakthroughs in treatment options for gastrointestinal and autoimmune diseases. He characterized WuXi Biologics as a leader in CRDMO services, stating that the partnership stands to accelerate their IND filings, addressing significant unmet medical demands in the field of autoimmune diseases.

Sinorda Biomedicine, established in 2010, specializes in innovation-driven drug development focusing on serious health issues such as digestive tract diseases and immune disorders. They have developed a robust infrastructure including a bioinnovative drug technology platform and a clinical R&D team with extensive international experience.

WuXi Biologics is known for offering end-to-end solutions in drug development, having a skilled workforce of more than 12,000 employees across multiple countries including China, the U.S., Europe, and Singapore. Their commitment to sustainability also plays an essential role in their operations, where they prioritize green technology innovations that result in environmentally friendly CRDMO solutions.

As of the end of 2025, WuXi Biologics was supporting 945 client projects, underscoring its expansive influence in the biotech landscape. This partnership with Sinorda Biomedicine could be a crucial step towards addressing urgent health needs and making innovative biologics more accessible for patients worldwide.

In conclusion, the collaboration between WuXi Biologics and Sinorda Biomedicine presents a significant advancement in the landscape of biopharmaceutical development, especially in the treatment of inflammatory bowel disease and other autoimmune disorders. As they move forward with their plans, the global medical community will be closely watching the progress and impact of SND006. This partnership not only signifies a step towards therapeutic innovation but also highlights the critical importance of collaborations in the biopharmaceutical industry.